ESMO 2025 | Metronomic chemotherapy and cemiplimab in recurrent/metastatic HNSCC
Marcelo Bonomi, MD, The Ohio State University, Columbus, OH, discusses a Phase II Trial (NCT04862650) of low-dose weekly metronomic carboplatin and paclitaxel with cemiplimab for first-line treatment of recurrent or metastatic head and neck squamous cell cancer (HNSCC). The regimen showed meaningful clinical activity and a manageable toxicity profile, supporting its potential as a more tolerable immunochemotherapy option for this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The idea of doing these studies, older population, meaning patients 70 and older, is the highest population that we are having these days. The fastest growing population, 45% of our patients are older than 70 and many of them will not tolerate standard doses of chemotherapy with immunotherapy. So the purpose of this study was to see if ultra-low doses of chemotherapy in combination with immunotherapy improve the outcomes of this patient population...
The idea of doing these studies, older population, meaning patients 70 and older, is the highest population that we are having these days. The fastest growing population, 45% of our patients are older than 70 and many of them will not tolerate standard doses of chemotherapy with immunotherapy. So the purpose of this study was to see if ultra-low doses of chemotherapy in combination with immunotherapy improve the outcomes of this patient population. This is what we saw. 45% of the patients will have a good response to this treatment. It’s very tolerable and most of these patients that respond to the therapy will have long-term survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
